seekingalpha.com · 20 jul

UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat

UroGen Pharma is shifting NMIBC treatment from surgery to office-based chemoablative therapy with ZUSDURI, driving a differentiated investment thesis. ZUSDURI revenue surged 109% sequentially to $29.2M in Q1 2026; repeat prescribers and workflow integration signal durable adoption and positive operating leverage. URGN's premium valuation is justified by a $5B+ TAM, durable clinical data, patent protection to 2044, and a de-risked pipeline including UGN-103.

globenewswire.com · 15 jul

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

fool.com · 12 jul

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds. The sale represented 8% of the insider's direct equity holdings in the company, as reported in the Form 4.

globenewswire.com · 8 jul

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

zacks.com · 7 jul

Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?

Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

fool.com · 30 jun

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?

10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $35.01 per share on June 22, 2026. The sale represented 7.15% of Mark Schoenberg's direct holdings, reducing his position from 139,763 to 129,763 shares of common stock.

fool.com · 14 jun

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share. The transaction represented 3.60% of Mark Schoenberg's direct holdings, reducing his position from 144,985 to 139,763 shares.

seekingalpha.com · 10 jun

UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript